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The ATP-binding cassette transporter G1 (ABCG1) is a cholesterol lipid efflux pump
whose role in tumor growth has been largely unknown. Our transcriptomics revealed
that ABCG1 was powerfully expressed in rapidly metastatic, aggregative colon cancer
cells, in all the ABC transporter family members. Coincidently, genetic amplification of
ABCG1 is found in 10–35% of clinical samples of metastatic cancer cases. Expression
of ABCG1 was further elevated in three-dimensional tumoroids (tumor organoids)
within stemness-enhancing tumor milieu, whereas depletion of ABCG1 lowered cellular
aggregation and tumoroid growth in vitro as well as hypoxia-inducible factor 1α in
cancer cells around the central necrotic areas in tumors in vivo. Notably, depletion
of ABCG1 triggered the intracellular accumulation of extracellular vesicles (EVs) and
regression of tumoroids. Collectively, these data suggest that ABCG1 plays a crucial
role in tumorigenesis in metastatic cancer and that depletion of ABCG1 triggers tumor
regression with the accumulation of EVs and their derivatives and cargos, implicating a
novel ABCG1-targeting therapeutic strategy by which redundant and toxic substances
may be accumulated in tumors leading to their regression.
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INTRODUCTION
The mechanism underlying unlimited tumor growth and
metastasis are unsolved problems in medicine and biology.
We have approached these issues by: (i) study of differently
metastatic cancer cells (1, 2), (ii) using a three-dimensional (3D)
organoid/tumoroid developed in stemness-enhancing medium
compared with popularly-used two-dimensional (2D) culture
milieu (2), and (iii) characterization of extracellular vesicles
(EVs) secreted by metastatic cancer cells (2–4). We have shown
that the rapidly metastatic cell line LuM1 robustly expressed
matrix metalloproteinase (MMP)-3 and -9, key proteins in
invasion and metastasis whose targeting using siRNA powerfully
attenuated subcutaneous tumor growth and metastasis in vivo
(1). Along with determining such key roles of MMP-3/9, we
found a distinct transcriptome of the ATP-binding cassette
(ABC) transporter family members in the LuM1 compared
with slowly or non-metastatic cell lines. ABC family proteins
have been shown to transport numerous kinds of molecules,
including inorganic anions, metal ions, peptides, amino acids,
sugars, and a large number of hydrophobic compounds and
metabolites across the plasmamembrane, and across intracellular
membranes (5, 6). Among most of the 50 ABC genes contained
in the human genome, the ABCG1 gene product plays eﬄux
roles for hydrophobic compounds, lipid and cholesterol (5–8).
For instance, in arterial macrophages ABCG1 pumps cholesterol
out of the cells leading to reverse cholesterol transport to
livers (9). ABCG1 also plays a critical role in mediating
cholesterol eﬄux to high-density lipoproteins (HDL) and
preventing cellular lipid accumulation (10, 11). Recent studies
showed that ABCG1 was crucial for cancer-initiating/stem cell
(CIC/CSC) survival of gliomas (12, 13). It was also shown that
conventional chemo/radio-therapy only targets rapidly dividing
cells and resistant CIC/CSC pool surviving such therapies
undergoes tumor relapse with the expression of drug eﬄux
ABC transporters (14). However, roles for ABCG1 in tumor
progression have not been completely clarified yet and require
further study. Therefore in the present study, we have aimed to
investigate whether ABCG1-mediated extracellular vesicle (EV)
lipid eﬄux altered tumor growth.
Transport and metabolism of lipids, lipoproteins and their
cargoes are involved in the functions of EVs. EVs are secreted
structures surrounded by lipid bilayer membranes containing
a variety of molecular cargoes (15–19). Depending on the
mechanisms underlying their release and biogenesis, EVs have
been classified as exosomes (30–200 nm), microvesicles (MVs)
(100–1,000 nm), apoptotic bodies (1,000–5,000 nm), and matrix
vesicles (20–23). EVs, and in particular exosomes usually contain
tetraspanins including CD9 (24) while cancer exosomes are often
enriched with epithelial cell adhesion molecule (EpCAM), which
is highly expressed in CIC/CSC (2, 3, 25, 26). Tumoroids with
enhanced CIC properties robustly secrete exosomes carrying
increased levels of CD9 and EpCAM (2). Tumors may often
Abbreviations: ABC, ATP-binding cassette; CIC, cancer initiating cell; CSC,
cancer stem-like cell; EV, extracellular vesicle; HIF, hypoxia-inducible factor; TIC,
tumor initiating cell.
originate from the transformation of normal stem cells, and
cancer cells may include sub-populations of CIC/CSCs (27–29).
We also showed that metastatic oral squamous cell carcinoma
cells markedly secrete EVs enriched with stemness marker
molecule EpCAM, oncogenic EGFR, and stress resistant proteins
HSP90s, whose targeting reduced survival of the metastatic cells
(3). Recently, it has become clear that EVs play a key role in cell-
to-cell communication and participate in a range of biological
events (30, 31). Roles for exosomes in the metastatic process
are observed not only in their role of setting/preparing the
pre-metastatic and metastatic niche (32) but also in inducing
a transformation in mesenchymal stem cells with a key role
in the tumor milieu (33, 34). We recently showed that anti-
EGFR therapeutic antibody cetuximab is secreted with EVs by
oral squamous cell carcinoma cells (4), suggesting that cancer
cells could secrete redundant and toxic substances using this
process. Many studies have examined paracrine or endocrine
roles for EVs, but neither autocrine manner of EVs nor their
lipidmetabolism have yet been deeply investigated. In the present
study, we therefore aimed to investigate the autocrine roles of
EVs involving ABCG1-mediated EV lipid metabolism using 3D
tumoroid model.
Tumor cell lines have been cloned using their abilities to
attach to tissue culture plates and thus the most adhesive cells
grow on the plates showing flattened morphologies. However,
we found that the LuM1 cells particularly form 3D aggregates
even on the two-dimensional (2D) tissue culture plates (see
later figures). We have shown that cancer cell aggregation led
to formation of hypoxic tumoroids with robust secretion of
EpCAM-exosomes and marked upregulation of reprogramming
and stemness genes as increased CIC/CSC traits (2). A term of
cellular “reprogramming” has been major after the development
of induced pluripotent stem (iPS) cells (35–37) andmore recently
used in cancer studies as well (38–42). Intra-tumoral hypoxia,
as well as a hypoxic milieu, can increase CIC/CSC properties
through the hypoxia-inducible factor 1α (HIF-1α)-mediated
induction of CIC/CSC genes, oncogenes, and ABC transporter
genes (2, 43–45). In the central area of tumors when enlarged,
elevated HIF-1α reprograms glycolysis and subsequent stemness
with increases in reprograming/pluripotency factors such as c-
Myc, Oct4, and Lin28 (38).
In the present study, we first aimed to screen and select
ABC genes that become powerfully expressed in the metastatic
aggregative cells, initially considering all the family members.
We then carried out loss-of-function analysis of such a family
member- ABCG1, to investigate whether this pump is involved
in tumorigenesis with elevated HIF-1α level. We then showed
that depletion of the ABCG1 pump triggers the accumulation of
autocrine EVs that could trigger regression of malignant tumors.
METHODS
Cells
A murine colon adenocarcinoma cell line Colon26, its low-
metastatic subline NM11, and high-metastatic subline
LuM1 were maintained in RPMI1640 supplemented with
10% FBS, penicillin, streptomycin, and amphotericin B in
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tissue culture plates or dishes (the 2D culture condition)
(2, 46). For photomicrography, a Floid cell imaging station
(ThermoFisher Scientific, Waltham, MA), BZ-X700 fluorescence
microscope (Keyence, Osaka, Japan), and Array Scan High
Content Screening System (Thermo, Waltham, MA) were used.
For 3D culture milieu, cells were cultured in NanoCulture
Plates (NCPs) (MBL Corporation, Nagoya, Japan) unless
otherwise specified (2, 47). For stem-cell conditions, cells were
cultured in mTeSR1 medium (Stem cell technologies) containing
LiCl (1mM), basic FGF (100 ng/ml), TGF-β (23.5 picomole),
GABA (1mM), insulin (4µM), transferrin (0.137µM), β-
mercaptoethanol (0.1mM), cholesterol (1.12µM), lipids, and
BSA in the DMEM/F12 basal medium (48).
Quantification of Hypoxia Levels and
Cellular Aggregates
As described by Eguchi T. et al. (2), hypoxia probe Lox-1 (MBL
Corporation, Nagoya, Japan) was added at a final concentration
of 2µM the day before the measurement. For analysis of hypoxic
cell aggregates in the 2D milieu, 10 k cells were seeded in 96-well
2D culture plates and hypoxia levels were measured 5 days later.
For analysis of spheroids and cell aggregates in the 3D milieu,
cells were seeded at a concentration of 4,000–10,000 cells/well in
96-well NanoCulture Plates (NCP) (MBL Corporation, Nagoya,
Japan) and sizes of cell aggregates were measured 3 or 7 days
later by using the hypoxia probe. Relative hypoxia levels were
measured using Array Scan High Content Screening System
(Thermo, Waltham, MA). The fluorescence intensity of each
pixel (µm2) and per aggregates of the cells was determined
using a filter set for TRITC. Fluorescent areas greater than 300
µm2 were counted as cellular aggregates, while those less than
300 µm2 were not. A single well-area of a 96-well plate was
sectionized to 9 fields, and the area of 1 field is 2,632 µm2.
For counting cellular aggregates, fluorescent intensity and area
(µm2 = pixel) of each aggregate in the entire cell population or
per field were calculated.
Gene Expression Profiling and
Bioinformatics
Cells were cultured for 3 days and total RNA was extracted
using the AGPCmethod with Trizol (Molecular Research Center,
Cincinnati, OH). cDNA was synthesized from 0.1 µg of total
RNA using a Low Input Quick Amp Labeling Kit (Agilent
Technologies, Santa Clara, CA), then hybridized to probes of a
SurePrint G3Mouse GE 8× 60K v.2 Microarray system (Agilent
Technologies, Santa Clara, CA). To generate heat maps of relative
and absolute expression levels, the raw data were input to MeV
4.0 software (http://www.Tm4.org/mev.html). Members of ABC
transporter genes were listed from references (8). Hypoxia-
related genes were listed (44). CSC marker genes were listed (49,
50). Raw data were submitted to the Gene Expression Omnibus
(GEO) database repository; accession ID: GSE97166; colon26,
GSM2553008; LuM1, GSM2553009; NM11, GSM2553010.
RNAi
A mixture of siRNA with four different sequences was used with
UU-3′ overhang for both strands. The sequences of sense strands
of siRNA ABCG1 were 5′-GAA GAA GGU GGA CAA CAA, 5′-
GAU GUG AAC CCG UUU CUU U, 5′-CGA AUC ACC UCG
CAC AUU G, and 5′-AGA CAG ACC UGC UCA AUG G. The
sequences of non-targeting dsRNAwere 5′-UAGCGACUAAAC
ACA UCA A, 5′-UAA GGC UAU GAA GAG AUA C, 5′-AUG
UAU UGG CCU GUA UUA G, and 5′-AUG AAC GUG AAU
UGCU CAA-3′.
Transfection
For RT-qPCR, siRNA (50 or 100 nM) was transfected by using
DharmaFECT 1 transfection reagent (Thermo Fisher Scientific,
Rockford, IL) according to the manufacturer’s instruction. Cells
were further cultured for 2 days for RT-qPCR analysis. Otherwise,
40 pmol siRNA was transfected into 500 k cells by using NEPA21
electroporator (NEPA Gene, Ichikawa, Japan). The condition of
electroporation was optimized by testing several conditions for
each cell line and the condition #6 (150V, 5ms) or #3 (125V,
2.5ms) were used for LuM1 cells. Cells were cultured for 6
days post-electroporation period and then used for subcutaneous
injection, western blot analysis, cell proliferation analysis, and cell
aggregation analysis.
RT-qPCR
Relative mRNA levels were quantified as described (51). For
quantification of gene expression levels with accuracy, Hprt1,
Hplp0, Hplp4, H3f3a, B2m, Gapdh, and Actb were examined as
candidates of internal controls andHprt1 andHplp0were used as
an appropriate internal control. The following primer sequences
were used: murine Abcg1 Fw, 5′-TTG ACA CCA TCC CAG CCT
AC-3′; murine Abcg1 Rv, 5′-AGC CGT AGA TGG ACA GGA
TG-3′; murine Hprt1 Fw, 5′-TGC TCG AGA TGT CAT GAA
GGAG-3′; murineHprt1 Rv, 5′-AAT CCAGCAGGTCAGCAA
AG-3′; murine Abcg2 Fw, 5′-TCG CAG AAG GAG ATG TGT
TG-3′; murine Abcg2 Rv, 5′-TTG AAA TGG GCA GGT TGA
GG-3′; murine Hif1a Fw, 5′-TCA TCA GTT GCC ACT TCC
CC-3′; murine Hif1a Rv, 5′-ATG TAA ACC ATG TCG CCG
TC-3′.
Western Blot Analysis
As described (52, 53), protein samples were loaded onto 10%
polyacrylamide gel, transferred to a PVDF membrane by using a
semi-dry method. Blocking and antibody reactions were done in
blocking buffer containing 3% skim milk (Wako, Osaka, Japan)
in Tris-buffered saline containing 0.05% Tween 20 (TBS-T).
An anti-ABCG1 antibody (N-term) (1:1,000, AP6529A, Abgent,
Jiangsu, China) and HRP-conjugated anti-GAPDH antibody
(1:5,000, Wako, Osaka, Japan) were used.
Cell Proliferation and Viability Assay
As described by Eguchi T. et al. (2), cells were seeded at a
concentration of 1 × 104 cells/well in a 96-well culture plate
(2D) or 96-well NCP (3D) and culture for 7 days. The cells
were separated by using Trypsin/EDTA solution and counted
by using Countess automated cell counter (Invitrogen, Carlsbad,
CA). To examine LuM1 proliferation altered by EVs, recipient
LuM1 cells were transfected with ABCG1-targeting or control
siRNA and seeded at a concentration of 1 × 104 cells per well
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in a 96-well plate. The cells were cultured for 24 h in serum-
containing medium to which LuM1-derived EVs (LuM1-EVs)
were added. NucBlue (ThermoFisher Scientific) was added to the
medium and number of cells at 3 hours post-EV addition period
was counted using Array Scan High Content Screening System
(Thermo, Waltham, MA).
For cell viabilities in tumoroid culture, cells were transfected
with 15 pmol/ml of siRNA in a 6-well plate. The transfected cells
were detached with trypsin and reseeded in 96-well 2D-culture
plates or NCPs at a concentration of 10 thousand cells per well
within DMEM contained with 10% serum or mTeSR1 stem cell
medium. Cells were detached using trypsin and counted using
a Countess cell counter at day 2, 4, and 6 post-seeding periods
(n= 4).
Preparation and Analysis of EVs
As described by Ono K et al, EVs were prepared using
polymer-based precipitation method (3). As described (2, 3),
EVs were visualized with 20,000 times magnification with an H-
7650 transmission electron microscope (Hitachi, Tokyo, Japan)
at Central Research Laboratory, Okayama University Medical
School. For particle diameter distribution analysis, a part of EV
fraction was diluted within PBS (–) to volume up to 40 µl and
then analyzed using Zetasizer Nano ZSP (Malvern Panalytical,
Malvern, UK) in a range of 0.3–10,000 nm-diameters (3).
EV Lipid Transport Analysis
For fluorescence labeling of EVs, 20 µg of EV was incubated
with 10µMBODIPY TRCeramide (ThermoFisher Scientific) for
20min at 37◦C. Excessive BODIPY TR Ceramide was removed
using Exosome Spin Columns (MW 3000) (ThermoFisher
Scientific). Cells were grown for 7 days on 2D culture plates
after transfection. As recipients, the cells were seeded at a
concentration of 1× 104 cells/well in a 96-well plate and cultured
for 24 h in an above-mentioned serum-containing medium. EVs
labeled with red fluorescent sphingolipid described above were
added to culture media of the recipient cells at the concentration
of 1.0 µg/well for 3 or 24 h. Hoechst33342 dye (NucBlue R©,
ThermoFisher Scientific) was added 1 h before the following
analysis. The number of cells and fluorescence were measured by
using Array ScanHigh Content Screening System (ThermoFisher
Scientific) as described (2). Filters for TRITC and Hoechst 33342
were used. The integrated fluorescence intensity of each cell was
calculated and the intensity of 500 or more was defined as an
EV positive cell while those less than 500 were not. For analysis
of EV-lipid accumulation in 3D tumoroids, we established and
used fluorescent LuM1 cells that stably expressed ZsGreen green
fluorescent protein driven by the murineMmp9 promoter (−600
to TSS). The cells were transfected with siRNA and reseeded
into 96-well NCPs at a concentration of 5 thousand cells per
well in mTeSR1 medium. The BODIPY TR ceramide-labeled
LuM1-derived EVs were added to the conditioned medium at a
concentration of 1 µg per well at day 4 post-seeding period and
the accumulation of the EV-lipids were monitored every 30min
for 24 h in the Array Scan system with channel 485/549/bright
field).
Animal Experiments
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the Japanese Pharmacological Society.
The protocol was approved by the Committee on the Ethics
of Animal Experiments of the Okayama University (Permit
Number: OKU-2015659). All surgery was performed under
sodium pentobarbital anesthesia, and all efforts were made to
minimize suffering. For knockdown studies, LuM1 cells were
transfected with ABCG1-targeting or control siRNA and cultured
for 6 days on 2D plates. Cells were pre-cultured on 2D plates and
detached with Trypsin/EDTA. The knockdown was confirmed
by Western blot analysis. Cells (5 × 105) were subcutaneously
transplanted into a side abdominal wall or on a back of each
BALB/c mouse (Japan SLC, Shizuoka, Japan) at 6–7 weeks old.
Primary tumors were resected 22 days later, then fixed with 4%
paraformaldehyde.
Immunohistochemistry
As described (2). Antibodies against ABCG1 (AP6529A, Abgent,
Jiangsu, China, 1:100), Ki67 (Dako M7248, Clone MIB-5) and
HIF-1α (CST D1S7W, 1:800) were used. To quantify positivity
rates of ABCG1 and HIF-1α, positivity of 1,000 cells in random
five fields around necrotic areas in tumors were measured under
high-power field.
Correlation Analysis of Gene Expression
With Cancer Prognosis
The meta-analysis of correlation between gene expression levels
and prognosis of patients were carried out using PrognoScan
(54) and survival analyses with Kaplan-Meier plots were
obtained.
Meta-Analysis of Genetic Alteration
To analyze alteration in APC in rectal, colon, colorectal,
and mucinous adenocarcinoma, cBioPortal was used. Genetic
alteration in ABC-G group genes were analyzed in whole data
(48,596 samples in 169 studies) available in cBioPortal version
1/4/2018, the breast cancer patient xenograft study (British
Columbia, Nature 2014; 117 samples), the metastatic breast
cancer project (Provisional, October 2017; 103 samples), and
NEPC (Trento/Cornell/Broad 2016; 114 samples) (55).
Statistics
Statistical significance was calculated using Microsoft Excel
or GraphPad Prism. The comparisons of 2 were done with
an unpaired Student’s t-test unless otherwise specified. The
comparisons of 3 or more groups were done with One-way
ANOVA with using pairwise comparison by Tukey’s multiple
comparisons test. Data were expressed as the mean± S.D. unless
otherwise specified. Box-and-whisker plots were expressed with
a median (center line), upper and lower quartiles, upper and
lower extremes, and a mean as ×. Minimum P-values, corrected
P-values, and COX P-values were calculated in PrognoScan.
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RESULTS
ABCG1 and ABCG2 Gene Expression Was
Elevated in Aggregative Metastatic Cells
We examined the gene expression levels of the ABC genes
among the aggregative metastatic cells compared to non-
aggregative less-metastatic cells by analyzing their transcriptome.
The absolute and relative expression levels ofAbcg1 in LuM1 cells
were significantly higher than the two slowly metastatic cell lines,
as well as higher than those of a number of the other members of
the ABC transporters (Figure 1A). The relative expression level
of Abcg2 was 204-fold higher in LuM1 cells than that in Colon26
cells, although the absolute expression level of Abcg2 was not at a
profound level (Figure 1A). The mRNA levels of ABCG1, as well
as ABCG2, were however elevated in the aggregated LuM1 cells
compared to non-aggregative Colon26, confirmed by RT-qPCR
analysis (Figure 1B,C).
The different metastatic traits of LuM1, NM11, and their
parental Colon26 had been shown previously, although their
morphological traits have not yet been studied.We therefore next
investigated the morphologies of these cell populations in vitro.
Cells derived from these three lines formed spindle shapes when
they were growing sparsely at days 1–3. Of note, however, only
LuM1 cells formed 3D-aggregates when they became confluent
at days 4–6 (Figure 1D, arrows 1E). These data suggested that
the metastatic nodule-forming LuM1 cells had an advanced
plasticity with regard to aggregative properties in the 2D culture
milieu.
We next confirmed that the differential metastatic traits
of these cell lines were retained after being maintained in
vivo. We injected LuM1 and Colon26 cells subcutaneously into
immunologically normal syngeneic mice. The LuM1 injected
group showed higher tumor incidence (75 vs. 25%) and the
higher number of metastatic nodules (17.8 ± 9.9 vs. 1.0 ± 1.0)
compared with the Colon26 injected group (Figure S1). These
findings indicated therefore that expression of the Abcg1 and
Abcg2 was elevated in colon cancer cells with rapidly metastatic
and aggregative traits.
Increased Production of ABCG1 and EV,
but Low Level of Ki67 in Tumoroids in vitro
It was shown that some CIC with CSC-like properties grow very
slowly (2). We have shown that tumoroids of metastatic prostate
cancer cells with enhanced stemness produce more proteins and
EVs compared with serum-stimulated differentiating cells (2).
These findings prompted us to examine whether production of
ABCG1, a marker of proliferating cells Ki67, and EV proteins
increased in stemness-enhanced tumoroids of the colon cancer
cells compared with serum-stimulated differentiating aggregates.
The tumoroids formed in the 3D/stem condition produced
more proteins than serum-stimulated cells (Figure 2A). Indeed,
ABCG1 levels per cells were higher in the tumoroids with
enhanced stemness than those in 2D-cultured serum-stimulated
differentiating cells (Figure 2B).
To examine expression and localization of ABCG1 and Ki67,
immunohistochemistry was performed on stemness-enhanced
or serum-stimulated tumoroids. The levels of ABCG1 were
higher in stemness-enhanced tumoroids (3D/stem) than those
in serum-stimulated tumoroids (Figure 2C, top). In contrast,
Ki67 levels were higher in serum-stimulated tumoroids than that
in stemness-enhanced ones (Figure 2C, bottom), as expected.
ABCG1 was found in whole tumoroids and particularly strong
positivity of ABCG1 was found at the marginal area of these
structures (Figure 2C, top), suggesting a transporter role for
ABCG1 in tumoroids and potentially in tumors. Ki67 was found
in the peripheral area of the tumoroids but in neither central
area nor the rind area. Thus, it was suggested that ABCG1
could play a transporter role between outside and inside of the
tumoroids.
It is known that EVs could transport substances between
cells. We therefore next compared EV protein secretion between
aggregated LuM1 and flat-cultured Colon26 cells. The aggregated
LuM1 cells secreted more EVs (approximately 8 µg EV proteins
/ a cell; EV vs cell protein ratio = 3: 100) compared with
Colon26 cells (Figures 2D,E, Figure S2). However, ABCG1 was
not found in the LuM1-derived EVs (data not shown), indicating
that ABCG1 plays a role in cells in tumors but is not secreted with
EVs. These findings suggested that while production of ABCG1
and EV increased, the number of Ki67 positive, proliferating cells
was lowered in tumoroids.
Targeting of ABCG1 Reduced Tumor
Growth in vitro and in vivo
To investigate a role for ABCG1 in tumoroids with enhanced
stemness, we next optimized efficient knockdown of ABCG1
prior to functional studies. One has experienced that mRNA
levels of housekeeping genes such as Gapdh and Actb were
altered according to cellular contexts. Therefore, we asked
an appropriate internal control for RT-qPCR and found that
Hprt1 was the one (Figure S3). By using Hprt1 as an internal
control, we confirmed that the expression of ABCG1 at the
mRNA level was significantly decreased after transfection of an
siRNA pool that targeted Abcg1 mRNA (Figure 3A). We next
established efficient transfection conditions and for depletion of
ABCG1 at the protein level. We examined ten conditions of
electroporation-mediated transfection and found that particular
combinations of voltage and pulse length were most efficient
(Figure S4). Using the optimized protocol, the level of ABCG1
was significantly decreased after transfection of the Abcg1-siRNA
pool at day 5 after the transfection (Figure 3B, Figure S5). To
investigate a role of ABCG1 in the spheroid formation by the
metastatic cells, we next examined whether depletion of the
transporter could alter LuM1 aggregation on the 3D culture
milieu. Indeed, depletion of ABCG1 significantly lowered the rate
of formation of cell aggregates larger than 1,000µm2 (Figure 3C,
Figure S6).
We next examined whether the morphology and viability
of tumoroids were altered by depletion of ABCG1. The
control tumoroids maintained viable morphologies while
disassembled dead cells appeared around the ABCG1-depleted
tumoroids (Figure 3D). Indeed, ABCG1 depletion significantly
reduced the viability of the stemness-enhanced tumoroids
(Figure 3E).
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FIGURE 1 | Transcriptome and morphologies of colon cancer cells with different metastatic potentials. (A) Heat map analysis of absolute expression levels of ABC
genes. Left, all ABC genes. Right, top 16 ABC genes expressed in LuM1 cells. C, Colon26; L, LuM1, N, NM11. (B,C) Relative mRNA levels of Abcg1 (B) and Abcg2
(C) analyzed using RT-qPCR. n = 4, biological replicates. *p < 0.05 (Mann-Whitney test). The mRNA levels were normalized with the levels of an internal control
Hprt1. (D,E) Representative photomicrographs of LuM1, NM11, and Colon26 cells at day 1 to day 6 (D) and day 4 (E) post-seeding period. Cells were cultured in a
serum-containing medium on 2D culture plates. Scale bar, 200µm. Arrows indicate cellular aggregates. Enlarged images of cells at day 4 was shown in (E).
We next investigated whether ABCG1 level was reduced in the
ABCG1 knockdown tumoroids. Tumoroids grown in 3D/stem
milieu showed ABCG1 positivity more extensively than the
organoids with serum-stimulation. The ABCG1 level in ABCG1-
siRNA transfected tumoroids was lower than control siRNA-
transfected ones (Figure 3F).
We next examined whether depletion of ABCG1
could alter expression of ABCG2 and the growth of the
metastatic cell line LuM1. We confirmed the expression
levels of Abcg1 mRNA were reduced with either 50 nM or
100 nM siRNA-ABCG1 (Figure S6). Abcg2 mRNA level was
reduced with 50 nM siRNA-ABCG1, but not significantly
reduced with 100 nM siRNA-ABCG1 (Figure S6). ABCG2
expression might be under the control of ABCG1. However, a
complex mechanism was indicated, which we describe in the
discussion.
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FIGURE 2 | Abundant production of ABCG1 and EV, but low level of Ki67 in tumoroids. (A) Representative morphologies (top) and protein concentration (bottom) in
tumoroids of LuM1 cultured in 2D/serum, 3D/serum, and 3D/stem conditions. n = 3, *P < 0.05, **P < 0.01, ***P < 0.005. Similar data were obtained from at least
two independent experiments. (B) Western blot showing ABCG1 in tumoroids developed in 3D/stem, 3D/serum, and 2D/serum conditions. β-actin, loading control.
Proteins per 10∧5 cells were loaded. (C) Immunohistochemistry showing ABCG1 and Ki67 in tumoroids. Cell nuclei were counterstained with hematoxylin. Scale
bars, 50µm. (D,E) Concentration of EVs in conditioned medium of aggregated LuM1 and Colon26 cells. EVs were prepared from serum-starved conditioned medium
for 1 or 2 days. EV protein concentrations per 106 cells (D) and per cellular protein concentration (E) were measured. n = 4, *P < 0.05, **P < 0.01.
These results indicated that targeting of ABCG1 led to
attenuation of tumor growth of the aggregative, metastatic cancer
cells.
Targeting of ABCG1 Reduced HIF-1α Level
in Subcutaneous Tumors
We next examined HIF-1α levels in vitro and in vivo and a role
of ABCG1 in tumor HIF-1α level. We found that more than
240 aggregates were formed by LuM1 in a 6-well plate while
less than 10 aggregates were formed by Colon26 and NM11
cells (Figure 4A). The hypoxia level of LuM1 aggregates was
75-fold higher than that of Colon26 and NM11 (Figure 4B).
Indeed, the cell aggregates formed by the LuM1 cells were
visualized with the red fluorescence of the hypoxia probe but
not in the Colon26 or NM11 cells, indicating that the aggregates
formed by LuM1 cells were markedly hypoxic (Figure 4C). As
HIF-1α would be predicted to be activated under these hypoxic
conditions, we next examined the gene expression profile of
Hif1a and its target genes in the hypoxic aggregates of LuM1
and the more normoxic Colon26 cells. Gene expression level of
Hif1a was significantly higher in LuM1 than that in Colon26
cells (Figure 4D). Upregulation of Vegfa mRNA (with 2 types
of probes) was found in LuM1 cells whereas downregulation
of Vegfa mRNA (with 2 other types of probes) was also
found in LuM1 cells, suggesting that alternative splicing of
Vegfamight be altered (Figure 4E). Although hypoxia-inducible
erythropoietin (EPO) gene expression was shown in human
neuroblastoma cells (56), downregulation of Epo mRNA was
found in LuM1 aggregates as compared with Colon26 cells,
We next examined whether ABCG1 depletion altered HIF-1α
levels in tumors. Strong positivity of HIF-1α and ABCG1 were
found close to the necrotic area in tumors (Figure 4E, left)
whereas reduced levels of these proteins were found around
the necrotic area in the ABCG1-depleted tumors (Figure 4E).
We quantified positivity rates of HIF-1α and ABCG1 around
the necrotic areas in tumors. The positivity rate of HIF-1α
as well as ABCG1 around necrotic areas were significantly
reduced in the ABCG1-depleted tumor compared with the
control tumor (Figures 4F,G). These findings indicated that
targeting of ABCG1 reduced the HIF-1α level around the central
necrotic area in tumors, suggesting potential anti-angiogenic
effects.
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Depletion of ABCG1 Triggered the
Accumulation of EVs and Reduced Survival
of Tumor Cells
It was shown that ABCG1 plays a critical role in mediating
cholesterol eﬄux to HDL and preventing cellular lipid
accumulation (11). It was also shown that oxidized lipoproteins
(57, 58) and phosphatidylcholine (59) were cytotoxic. These
studies prompted us to examine whether depletion of ABCG1
could trigger the accumulation of EV-derived substances
and alter the viability of tumor cells. We labeled the lipid
membrane of LuM1-derived EVs with sphingolipid-associated
red fluorescent material. We then investigated the accumulation
of the EV-derived red fluorescence taken up by ABCG1-depleted
or control LuM1 cells, firstly in the 2D-cultured system and
then into 3D tumoroids. EV-lipids were accumulated to a
greater extent in the ABCG1-depleted LuM1 cells compared
with the control cells (Figures 5A,B). Such differences in the
accumulation levels of EV-lipids between ABCG1-depleted
and control cells were found in 3 h after the addition of EVs
but were recovered in 24 h in the 2D cultured conditions
(Figures 5C,D). We next investigated EV-lipid accumulation
in 3D tumoroids with or without ABCG1-depletion. ABCG1
depletion significantly triggered the accumulation of EV-lipids
in tumoroids until 24 h after EV addition compared with the
control tumoroids (Figure 3E).
These findings suggested that depletion of ABCG1 triggered
the accumulation of EV-derived lipids.
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Cancer Prognostic Value of ABCG1
We next investigated the correlation ofABCG1/2 gene expression
in tumor clinical samples and prognosis of patients suffering
from a range of cancer types, by searching public database
PrognoScan (54), a tool for assessing the biological relationship
between a large collection of publicly available cancer microarray
datasets with clinical annotation. The correlation between
ABCG1/2 expression and poor prognosis of patients suffering
from colorectal cancer was found with an endpoint of disease-
specific survival (Figure 6A, Table S1), although this was not
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FIGURE 5 | Depletion of ABCG1 triggered accumulation of EVs and declined survival of tumor cells. (A–E) Depletion of ABCG1 increased accumulation of EV-derived
lipid in LuM1 cells in 2D-culture condition (A–D) and 3D tumoroids (E). LuM1-derived EVs were labeled with fluorescent sphingolipid and added to conditioned media
of ABCG1-depleted or control LuM1 cells. (A) Accumulation levels of EV-lipid. Accumulation levels per cell at 3 h post-EV addition period were shown. **P = 0.0004,
n = 4 (biological replicates). (B) The rate of EV-lipid-accumulated cells. The rate of EV-lipid accumulated cells at 3 h post-EV addition period was shown.
**P = 0.0003, n = 4 (biological replicates). (C) Kinetics of EV accumulation in the 2D-cultured LuM1. **P = 0.0004, n = 4 (biological replicates). (D) Representative
images of cells with EV-lipid accumulation at 3 or 24 h post-EV addition periods. Red fluorescence indicates EV-lipid. DNA was stained with Hoechst33342 (blue).
Scale bars, 200µm. (E) Accumulation levels of EV-lipid in 3D tumoroids. *P < 0.05, **P < 0.01, ***P < 0.001, n = 8 (biological replicates).
consistent among total nine cohort studies of colorectal cancer
available in the meta-analysis. A significant correlation between
ABCG1 expression and poor prognosis in a breast cancer cohort
study was found with an endpoint of distant metastasis-free
survival with a minimum P-value 0.00097 (Figure 6B, Table S1).
The correlation between ABCG1 (P = 0.00715) or ABCG2
(P = 0.0573) expression and poor prognosis of patients suffering
from head and neck cancer was found with an endpoint of
relapse-free survival (Figure 6C, Table S1). These data suggested
that high expression of ABCG1 in tumor clinical samples could
be a potential prognostic marker of metastatic breast cancer and
recurrent head and neck squamous cell carcinomas.
Genetic Amplification of ABCG Genes in
Resistant Cancer
We also showed that ABCG1 and ABCG2 were co-expressed
in the metastatic colon cancer cells. ABCG2 is also known as
breast cancer resistant protein (BCRP) that plays an eﬄux role
for anti-cancer drugs in chemoresistance (60, 61). To investigate
genetic aberrations that could influence gene expression of these
ABC genes, we searched alteration frequencies of ABC-G family
among a range of cancer types in cBioPortal (62), a public portal
database. Amplification of ABCG group genes was found in
55% of breast cancer patient-derived xenograft samples (16/29
samples) and in 28% of castration-resistant prostate cancer
samples (Figure S7a). However, amplification of ABC-G genes
were not found in colorectal cancer clinical samples. Among the
five genes of the ABC-G group, ABCG1 was the most frequently
altered (Figures S7b–e). Therefore, genetic amplification and
cancer cell aggregation with increased stemness can increase
levels of ABC-G group proteins that can be correlated with and
be useful for prognosis of cancer endocrine resistance.
DISCUSSION
We showed ABCG1 to be markedly expressed inmetastatic colon
cancer cells, their tumoroids as well as in subcutaneous tumors
(Figures 1, 2). Genetic amplification of ABCG1 is found in
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10–35% of clinical samples ofmetastatic cancer cases (Figure S7).
Coincident with increased secretion of EVs and accumulation of
proteins, cellular ABCG1 was increased when tumoroids became
enlarged (Figure 2). Depletion of ABCG1 reduced growth of
the tumoroids (Figure 3) and lowered levels of HIF-1α around
the central necrotic areas in tumors in vivo (Figure 4). This
appears highly conceivable, inasmuch as the metastatic colon
cancer cells, tumoroids and tumors derived from them express
high level of ABCG1. Notably, depletion of ABCG1 increased the
accumulation of EVs in the tumoroids and declined their viability
inasmuch as potential loss of detoxification (Figures 3, 5, 6D).
These findings suggest that ABCG1 plays a crucial role in
tumor progression and that depletion of ABCG1 triggers the
accumulation of EVs, lipoproteins, and their cargo and tumor
regression.
Our study also touches upon anABCG1-mediatedmechanism
underlying tumor progression. We showed that depletion of
ABCG1 increased the accumulation of EVs, lipoproteins, and
their potential cargos in the metastatic cancer tumoroids leading
to reduction in their viability (Figures 3, 5). ABCG1 and ABCA1
plays a critical role in mediating eﬄux of cholesterol and
phospholipids, removing excess cholesterol and phospholipids
from cells, and preventing cellular lipid accumulation (10, 11).
Cholesterol and phospholipids are essential to the body and
cells, but an excess of cholesterol or lipids is toxic and a risk
factor for arteriosclerosis (63), and is presumably toxic for
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tumors as well. Reactive oxygen species generate oxidized low-
density lipoproteins (oxLDL) (64) and oxidized lipoproteins and
phosphatidylcholine are cytotoxic (57–59). Thus, we conjectured
that that tumors are protected from toxic lipid products by
ABCG1-mediated detoxification (Figure 6D).
The 3D hypoxic tumoroids grow very slowly but produced
robust levels of ABCG1 and EVs in stemness-enhancing milieu,
indicating a reprogrammed metabolism in tumoroids, also
suggested in our previous studies (2). Depletion of ABCG1
led to reduced HIF-1α levels around the central necrotic
area in tumors. It was shown that HIF-1α is increased in
the central areas in tumors, where this transcription factor
activates glycolysis gatekeeper PDK1 gene leading to enhancing
glycolysis and subsequent induction of reprogramming factors
(38). Surprisingly, ABCG1 is an upstream regulator of such a
crucial signaling of HIF-1α. We first oppositely hypothesized that
HIF-1α could activate ABCG1 gene transcription inasmuch as
two HIF-1α-binding sites were found in ABCG1 gene promoter
region; however, this retrograde pathway arose from our present
studies. ABCG1 was expressed not only hypoxic area but
broad area in tumoroids and tumors and our results suggest
the oppositely aligned regulatory axis ABCG1-to-HIF1. It was
shown that extracellular HDL binding to scavenger receptor
SR-B1 promotes nuclear translocation of HIF-1α via the PI3K-
Akt pathway (65), which may be activated in tumors. We are
currently investigating further mechanisms underlying ABCG1-
mediated HIF1 activation and tumor growth.
Analyzing PrognoScan database indicated that elevated
expression of ABCG1 and ABCG2 were correlated with poor
prognosis of patients suffering from colorectal cancer and head
and neck squamous cell carcinoma. We also found that Abcg2
/ Bcrp mRNA level was increased in the rapidly metastatic,
aggregative LuM1 cells as compared to the slowly metastatic
parental Colon26 cells, although the absolute expression level
of Abcg2 was very low (Figures 1A,C). It has been shown
that HIF-1α trans-activates ABCG2 gene under hypoxia (66,
67). Therefore, it is conceivable that Abcg2 expression was
induced in the hypoxic aggregation of cancer cells. It was
also shown that ABCG2 level was increased in ovarian tumor-
initiating cells (TIC/CIC/CSC) and depletion of either HIF-
1α or ABCG2 reduced tumorsphere (cell aggregate) formation,
demonstrating HIF-1α-to-ABCG2 axis in hypoxic tumorsphere
(68). We showed that depletion of ABCG1 reduced HIF-1α
around the necrotic area of a tumor. Therefore, it is conceivable
that ABCG1 depletion could also reduce Abcg2 expression level
through reduction of HIF-1α (the hypothetical regulatory axis
is ABCG1>HIF-1α>ABCG2). Depletion of ABCG1 reduced
ABCG2 mRNA level, but this was not siRNA-concentration-
dependent manner, suggesting a complex regulatory mechanism
(Figure S6). It has been shown that ABCG2 is a drug eﬄux
pump that involves chemoresistance in cancer (60, 61, 69,
70). Depletion of the drug eﬄux pump ABCG2 increased
chemo-sensitivity to paclitaxel, cisplatin, and imatinib through
intracellular accumulation of these drugs (68). Distinctively,
ABCG1 is a lipid eﬄux pump.We demonstrated that depletion of
ABCG1 triggered the intracellular accumulation of EV-lipid and
reduction of the cancer cell viability. Intratumoral accumulation
of EV-lipid may be cytotoxic.
We approached tumor milieu using stemness-enhancing
medium with 3D culture milieu, which increased tumorigenesis
as well as intra-tumoral hypoxia in vitro. In addition, acidic
milieu are particular traits that increase tumor malignancy (71–
73). Acidic milieu is caused by increased extracellular proton
and lactate. A macrophage lineage osteoclasts also create an
acidic extracellular milieu by secretion of protons via vacuolar
H+-ATPase (v-ATPase) proton pumps during bone resorption.
Bone-colonized cancer cells also release protons and lactate
via plasma membrane pH regulators to avoid intracellular
acidification resulting from increased aerobic glycolysis known
as the Warburg effect (74). Activities of proton pumps increase
acidity in tumor milieu and in intracellular vesicles such
as lysosomes and phagosomes, from which multi-vesicular
bodies (MVB) and exosomes are generated. Therefore, the
acidic milieu could increase exosome biosynthesis and secretion
via altering the properties of lysosomes and MVBs. Indeed,
microenvironmental acidosis was shown to stimulate cancer
cells to secrete exosomes, an effect which were inhibited by
proton pump inhibitors (PPIs) (75, 76). In our studies, cancer
cell aggregation also triggered secretion of EVs (Figure 2) (2).
Hence, we are currently challenging control and relation of
aerobic glycolysis that generates lactate acidic milieu, acidity in
intracellular vesicles, and molecular and secretory traits of EVs.
Glycolysis is likely to be amplified in the hypoxic cores of the
tumoroids, while diffusion of lactate out of these structures may
be slower due to the increased cell density.
ABCG1-mediated cholesterol eﬄux may involve lysosomal
activity / acidity that promote exosome secretion. ABCG1
and ABCA1 pump cholesterol out of cells (77) and therefore
depletion of the eﬄux pump ABCG1/A1 can result in lysosomal
accumulation of free cholesterol (FC). Increasing levels of
lysosomal membrane FC were shown to inhibit lysosomal
acidification (78). It was demonstrated that excess FC in the
lysosomal membrane leads to loss of acidity as a result of
inhibition of v-ATPase proton pumping activity in the lysosomal
membrane. Therefore, depletion of ABCG1 may trigger intra-
vesicular accumulation of FC, which inhibit v-ATPase activity
and reduce lysosomal acidity. Interestingly, PPIs also have a
pro-apoptotic effect to cancer cells (79), implicating a potential
accumulation mechanism similar with ABCG1-depletion.
EVs or nanovesicles such as exosomes and more canonically
liposomes have been broadly proposed for application and
ability to deliver anti-cancer and anti-disease drugs, including
theranostic molecules (80–85). However, we recently showed that
anti-EGFR therapeutic antibody cetuximab is secreted with EVs
by oral cancer cells (4), suggesting that cancer cells can secrete
toxic and redundant substances within EVs as a novel mechanism
underlying drug resistance. Low pH within melanomas was also
shown to promote the release of cisplatin-contained exosomes,
which PPI inhibited, suggesting a potent role for acidic milieu
in chemoresistance (86, 87). Not only cancer cells but also
tumor-associated macrophages can express ABCG1 that pump
cholesterol out, implicating that ABCG1 in tumor milieu may
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also play a detoxifying role. However, delivery of ABCG1-
targeting siRNA with EVs/nanovesicles may overcome such
EV-mediated drug resistance. Our allograft experiments and
3D tumoroid model have contributed to deeper understanding
and may be an important model for the tumor milieu. We
are currently developing a strategic method to deliver ABCG-
targeting siRNA with nanovesicles / EVs to tumors and their
acidic milieu.
In conclusion, we showed that (i) ABCG1 was robustly
expressed in the metastatic aggregative cells, in tumors derived
from them, and in some types of clinical cancer correlated with
poor prognosis of patients; (ii) depletion of the ABCG1 pump
triggered the autocrine accumulation of EVs and cancer cell
death in tumoroids, indicating a novel therapeutic strategy by
which redundant and toxic substances may be accumulated in
tumors by ABCG1-depletion, leading to their regression.
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Figure S1 | Tumorigenicity, a rapidly lung-metastatic ability, and an aggregative
property of the LuM1 cells. LuM1 and Colon26 cells (500 k cells) were
subcutaneously injected into side abdominal walls of BALB/c mice. Primary
tumors (a) and lungs (b) were resected on day 35 post-injection period.
Arrowheads indicate typical metastatic nodules. Scale bar, 5mm. (c) Tumor
incidence and lung metastasis of Colon26 and LuM1 cells. Data were expressed
as mean ± SEM.
Figure S2 | Morphological and size analyses of EVs. (a) Representative TEM
images of EVs secreted by LuM1 cells. Scale bars, 50µm. (b) Particle diameter
distribution of LuM1-EVs.
Figure S3 | RT-qPCR analysis to find an appropriate internal control and of
Abcg1 knockdown. (a) Relative mRNA levels of internal control candidates.
The vertical axes indicate relative expression levels. Higher values mean the
absolute expression levels were higher. LuM1 cells were cultured in no reagent
control medium or control siRNA transfected condition with the indicated
concentrations. Reference cDNA standards were prepared from the cDNA pool
of the LuM1 cells by step dilution. (b) RT-qPCR analysis of Abcg1. The Abcg1
expression levels relative to Hprt1 or Hplp0 were shown. n = 3, ∗P < 0.05,
∗∗P < 0.001.
Figure S4 | Optimization of electroporation-transfection to LuM1 cells. LuM1 cells
(550k cells) were transfected with 10 µg of pCMV-GFP with the indicated 10
different electroporation conditions. (a) Representative fluorescence images with
GFP at 24 h post-electroporation period. (b) A list of electroporation conditions,
gene transfer efficiencies, and cell viabilities.
Figure S5 | Full images of Western blot analysis of ABCG1 and GAPDH at day 5
post-electroporation transfection.
Figure S6 | Altered aggregation of LuM1 with or without ABCG1 depletion.
LuM1 cells were transfected with control or ABCG1-targeting siRNA by using
electroporation method and seeded at the concentration of 4,000 cells per
well in a 96-well 3D cell culture plate (NCP). (a) Box-and-whisker plot analysis
of hypoxic cell aggregates. A hypoxia probe Lox-1 was added on day 7
post-transfection period and the cell aggregates were scanned on day 8. (b)
Stacked bar graph showing rate of cell aggregates sized >5,000 µm2 (black),
1,000–5,000 µm2 (gray), and 300–1,000 µm2 (white). Control si group,
n = 143, Abcg1 si group, n = 111. (c,d) ABCG1 and ABCG2 mRNA levels
upon transfection of 50 nM or 100 nM siRNA-ABCG1 or -control. The mRNA
levels were normalized with Gapdh (c) or Hprt1 (d). ∗P < 0.05, ∗∗P < 0.01.
n.s., not significant. (c) n = 4 (biological quadruplicate), (d) n = 3 (biological
triplicate).
Figure S7 | Genetic alteration of ABC-G group in cancer. The data were
obtained by searching cBioPortal. (a–c) A combined study was carried out
containing samples from 169 studies. (a) Total alteration frequency of ABCG
group (ABCG1, G2, G4, G5, and G8) among the 169 cancer studies. (b,c)
Alteration frequencies of ABCG1 (b) and ABCG2 (c) among the 169 cancer
studies. (d) Genetic alteration of each ABCG gene in samples of breast cancer
xenograft and metastasis. Alteration frequencies in a combination of these two
studies (left) and of the PDX study only (right) were indicated. (e) Genetic
alteration of each ABCG gene in castration-resistant neuroendocrine prostate
cancer samples.
Table S1 | Correlation between ABCG1/G2 expression and prognosis of patients
suffering from colorectal cancer, breast cancer, and head and neck cancer were
investigated using the PrognoScan.
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Table S1. Correlation between ABCG1/G2 expression and prognosis of patients suffering from colorectal cancer, breast cancer and head and neck cancer were investigated using the PrognoScan. 
CANCER 
TYPE 
(SUBTYPE) 
Colorectal 
cancer 
Colorectal 
cancer 
Breast cancer Breast cancer 
Head and neck 
cancer (SCC) 
Head and neck 
cancer (SCC) 
ID_NAME ABCG1 ABCG2 ABCG1 ABCG2 ABCG1 ABCG2 
DATASET GSE17537 GSE17537 GSE12093 GSE12093 GSE2837 GSE2837 
N 49 49 136 136 28 28 
ENDPOINT 
Disease 
Specific 
Survival 
Disease 
Specific 
Survival 
Distant 
Metastasis 
Free Survival 
Distant 
Metastasis 
Free Survival 
Relapse Free 
Survival 
Relapse Free 
Survival 
COHORT VMC VMC 
IO, NCI, 
TUM, CCF 
(1992-2000) 
IO, NCI, 
TUM, CCF 
(1992-2000) 
VUMC, VAMC, 
UTMDACC 
(1992-2005) 
VUMC, VAMC, 
UTMDACC 
(1992-2005) 
ARRAY 
TYPE 
HG-
U133_Plus_2 
HG-
U133_Plus_2 
HG-U133A HG-U133A U133_X3P U133_X3P 
PROBE ID 204567_s_at 209735_at 204567_s_at 209735_at 
g8051574_3p_a
_at 
g12414050_3p_
at 
CONTRIBUT
OR 
Smith Smith Zhang Zhang Chung Chung 
CUTPOINT 0.265306 0.816327 0.764706 0.779412 0.714286 0.535714 
MINIMUM P-
VALUE 
0.136888 0.00331325 0.00097169 0.207877 0.00715101 0.0573061 
CORRECTED 
P-VALUE 
- 0.0682319 0.0248784 - 0.12506 - 
ln(HR-high / 
HR-low) 
1.42958 1.57101 1.37998 0.609279 1.4748 1.04415 
COX P-
VALUE 
0.714539 0.63975 0.00487242 0.793331 0.134986 0.755988 
ln(HR) 0.140739 0.152763 1.39334 0.131701 0.461254 -0.158272 
HR [95% CI-
low CI-upp] 
1.15 [0.54 - 
2.45] 
1.17 [0.61 - 
2.21] 
4.03 [1.53 - 
10.63] 
1.14 [0.43 - 
3.06] 
1.59 [0.87 - 
2.90] 
0.85 [0.31 - 
2.32]  
